Use of Follistatin-Like 1 (FSTL1) in Cardiometabolic Heart Failure

JP2025510782APending Publication Date: 2025-04-15REGENCOR INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024556439
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-04-01
Filing Date
2023-03-24
Publication Date
2025-04-15

Smart Images

  • Figure 2025510782000003
    Figure 2025510782000003
  • Figure 2025510782000004
    Figure 2025510782000004
  • Figure 2025510782000005
    Figure 2025510782000005
Patent Text Reader

Abstract

In particular, provided herein are compositions and kits comprising epicardium-derived paracrine factors such as follistatin-like 1 (FSTL1) for aiding in the treatment of cardiometabolic heart failure, and methods of using the same.A method for aiding in the treatment of cardiometabolic heart failure, comprising contacting cardiac tissue with a non-glycosylated follistatin-like 1 (FSTL1) polypeptide.A method for treating cardiometabolic heart failure, comprising contacting cardiac tissue with a non-glycosylated follistatin-like 1 (FSTL1) polypeptide.
Need to check novelty before this filing date? Find Prior Art